The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
Amgen said on Wednesday its drug helped to reduce the risk of flares in patients with an immune system-related condition, ...
Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Uplizna therapy reaches main goal in Phase 3 trial for IgG4-RD, cutting the risk of flare by 87% with no new safety events.
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin ...